HCAT

Rating neutralAI Memo

Health Catalyst

As of 2026-04-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Strategic review and CEO-transition clarity • 2026-08-06

Base target: $1 / p=45% prob

Biggest risk

The bear case is that retention weakened to 93%, near-term revenue headwinds are explicit, FY2026 guidance is withheld during a strategic review, and year-end liquidity fell sharply after debt repayment and acquisitions, leaving little room for another execution stumble [#PR-2026-03-12] [#10-K-2026-03-12].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The bull case is that Q4 showed better adjusted EBITDA, platform clients increased to 162, and the business mix is moving toward higher-margin technology revenue, so even modest execution improvement could re-rate a stock trading at distressed levels [#PR-2026-03-12] [#10-K-2026-03-12].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 revenue and EBITDA against March outlook
Technology-mix improvement must outweigh retention and liquidity pressure
The bull case is that Q4 showed better adjusted EBITDA, platform clients increased to 162, and the business mix is moving toward higher-margin technology revenue, so even modest execution improvement could re-rate a stock trading at distressed levels [#PR-2026-03-12] [#10-K-2026-03-12].

BearKey bullets

Additional impairment or acquisition integration issues damage confidence
Debt covenant or liquidity constraints tighten strategic flexibility
Further client downsell or Ignite migration disruption keeps retention under pressure

WatchKey bullets

Strategic review and CEO-transition clarity

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +105% / -45%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $1 (p=30%)

Commentary

Sentiment remains cautious-to-negative. Primary-source evidence supports a monitoring thesis, not a strong rebound call: profitability improved on an adjusted basis, but retention weakened, management withheld FY2026 guidance, and the leadership transition adds execution uncertainty while liquidity is materially lower than a year ago [#PR-2026-03-12] [#8-K-2026-04-03] [#10-K-2026-03-12].

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 revenue and EBITDA against March outlook
Technology-mix improvement must outweigh retention and liquidity pressure

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-06
Strategic review and CEO-transition clarity
Management is withholding full-year 2026 guidance during an internal strategic and operational review tied to the CEO transition, while the March 31 transition agreement keeps former CEO Daniel Burton as strategic advisor through December 31, 2026. Any update that restores guidance or clarifies cost actions and go-forward priorities could move the stock materially, but visibility remains limited today [#PR-2026-03-12] [#8-K-2026-04-03].
Prob 40.00% • Move 20.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Q1 2026 revenue and EBITDA against March outlook
2026-05-07
The nearest test is whether HCAT can deliver Q1 2026 revenue of $68-$70 million and adjusted EBITDA of $7-$8 million after Q4 revenue fell 6% year over year and dollar-based retention dropped to 93%; a clean print would help stabilize sentiment, but a miss would reinforce the ongoing reset [#PR-2026-03-12].
Prob 55% • Move 22% • Priced-in 60%

Long-term Catalysts

Months to a year

Technology-mix improvement must outweigh retention and liquidity pressure
2027-03-12
The longer-term setup depends on HCAT sustaining its shift toward technology revenue, which reached $208.3 million versus $102.9 million of professional services revenue in 2025, while preserving enough client retention and liquidity to work through Ignite migrations, TEMS downsell pressure, and covenant-bearing debt. The company ended 2025 with $95.7 million of cash, cash equivalents, and short-term investments, so execution matters more than narrative at this stage [#10-K-2026-03-12].
Prob 35% • Move 60% • Priced-in 35%

Risks

Additional impairment or acquisition integration issues damage confidence
Debt covenant or liquidity constraints tighten strategic flexibility
Further client downsell or Ignite migration disruption keeps retention under pressure
Q1 2026 miss versus the $68-$70 million revenue and $7-$8 million adjusted EBITDA outlook
Strategic review extends and full-year guidance remains absent

Peers

Symbol	Summary
ACH	Useful mainly as a small-cap healthcare comp by size; not a close operating peer, but relevant for framing how severely micro-cap healthcare names are discounted when execution visibility is weak.
LUCD	Another loose small-cap healthcare comparator by valuation and risk appetite rather than business model; helpful for judging downside sensitivity in speculative healthcare names.
ABT	A broad hospital-facing healthcare adjacency rather than a direct peer; the comparison mainly highlights how far HCAT trades below scaled incumbents because its software-and-services execution risk is much higher.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

Loading AI feed…

Symbol

Summary

ACH

Useful mainly as a small-cap healthcare comp by size; not a close operating peer, but relevant for framing how severely micro-cap healthcare names are discounted when execution visibility is weak.

LUCD

Another loose small-cap healthcare comparator by valuation and risk appetite rather than business model; helpful for judging downside sensitivity in speculative healthcare names.

ABT

A broad hospital-facing healthcare adjacency rather than a direct peer; the comparison mainly highlights how far HCAT trades below scaled incumbents because its software-and-services execution risk is much higher.